HER2-low
A group with low HER2 expression that is now discussed in some breast cancers.
Parent marker: HER2
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Clinical meaning
The HER2-low category is relevant because some antibody-drug conjugates show benefit in this group. Definitions and reporting are still evolving between facilities.
How this finding appears in a report
Detailed score reporting and, where available, in situ confirmation of results are required, as these groups are determined by scores.
When therapy stops working
Interpretation depends on the reporting standards used by the laboratory.
What needs verification
- Recent immunohistochemistry scores and whether assessments were performed on recent samples.
- Are there any confirmation results in situ?
- Compliance with the indications applicable in the country where the drug is used.
Marker context: HER2
In gastric cancer, HER2 status is often assessed by immunohistochemistry and confirmed by other methods when the results are ambiguous. In lung cancer, HER2 mutations are discussed differently from HER2 amplification.
A negative result does not always mean absent
Summary
- Gen
- ERBB2
- Variant
- HER2-low (IHC 1+ atau IHC 2+ tanpa amplifikasi)
- Alteration type
- Overexpression
- Discussed in
- Breast Cancer
- Updated
- 2026-09-10
Other names in reports
HER2 low
Drugs discussed
Treatment categories
Related guides
Sources
- NCI Dictionary of Cancer Terms(lembaga)
- ClinicalTrials.gov(registry)
Clinical trials
Studies mentioning marker HER2
Filtered from public study descriptions. Access status and site readiness remain unverified.
NCT06452277Phase 3Immunotherapy
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Lung Cancer | biomarker: HER2 | Immunotherapy, Chemotherapy
United States, Argentina, Australia +33279 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker HER2, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06452277Not verified
NCT07195695Phase 3Combination regimen
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Lung Cancer | biomarker: HER2 | Immunotherapy, Targeted therapy
United States, Argentina, Australia +25202 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker HER2, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07195695Not verified
NCT06324357Phase 1 / Phase 2Targeted therapy
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Stomach Cancer | biomarker: HER2 | Targeted therapy
United States, Belgium, China +7103 registry sites
Why this appears: Appears because it is recorded for Stomach Cancer, it mentions marker HER2, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06324357Not verified
NCT06123338Phase 2Combination regimen
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Stomach Cancer | biomarker: HER2 | Immunotherapy, Targeted therapy, Chemotherapy
United States10 registry sites
Why this appears: Appears because it is recorded for Stomach Cancer, it mentions marker HER2, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06123338Not verified
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- HER2
Biomarker
Reason: Related through a biomarker
- Breast Cancer
Cancer type
Reason: Related to this page
- Trastuzumab deruxtecan
Drug
Reason: Related to this page
- Targeted therapy
Treatment category
Reason: Related to this page
To check
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.